** Shares of drug developer AnaptysBio ANAB.O surge 28.3% to $15.88 in morning trade
** Co says its experimental drug, rosnilimab, met the main goal in a mid-stage trial for the treatment of rheumatoid arthritis, a chronic inflammatory disease that primarily affects the joints
** The main goal was to evaluate if the drug could significantly reduce symptoms in three dosages using a tool called DAS-28 CRP score, which measures the severity of the disease after 12 weeks in comparison with placebo
** ANAB says that the drug will be tested in patients with a type of bowel disease called ulcerative colitis by the second quarter of this year
** Stock fell 46% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。